Calixarene Compounds for Selective Glucocorticoid Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory therapies, particularly glucocorticoid treatments, come with severe side effects and an unmet need for alternative strategies that can effectively manage inflammatory diseases without the adverse effects associated with long-term use.
Innovation Solution
Development of novel compounds of general Formula (I), which exhibit anti-inflammatory, anti-oxidative, and lipid metabolism modulation properties, mimicking the effects of glucocorticoids and heparan sulfate, offering potential as new medicaments for treating inflammatory and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoid therapy is used to treat inflammatory diseases, then anti-inflammatory efficacy is improved, but severe side effects occur including hyperglycemia, muscle wasting, hypertension, osteoporosis and neurological symptoms
Solution Approach 1:
The patent segments the glucocorticoid receptor's functional domains to separate anti-inflammatory effects from side effect-causing effects. By designing compounds that selectively activate specific receptor conformations or tissue-specific isoforms, the invention achieves anti-inflammatory efficacy while avoiding metabolic and neurological side effects associated with traditional glucocorticoid therapy.
Solution Approach 2:
The invention applies local quality by creating compounds with selective tissue distribution and receptor binding characteristics. The calixarene derivatives are designed to preferentially bind to glucocorticoid receptors in inflamed tissues while minimizing interaction with receptors in metabolic and neurological tissues, thereby achieving localized anti-inflammatory action without systemic side effects.
2Duration of action of stationary object
If long-term chronic treatment with glucocorticoids is required for diseases with no cure, then sustained anti-inflammatory effect is achieved, but cumulative side effects increase in severity
Solution Approach 1:
The patent employs preliminary action by designing compounds that induce protective cellular adaptations before inflammatory damage occurs. The calixarene derivatives pre-activate anti-inflammatory pathways and upregulate protective genes in advance, creating a preventive effect that reduces the need for continuous high-dose therapy and thereby minimizes cumulative side effects during long-term treatment.
3Adaptability or versatility
If glucocorticoid receptor agonists are designed to separate helpful and harmful modulation of gene expression, then selective anti-inflammatory action is achieved, but drug discovery campaigns have been unsuccessful
Solution Approach 1:
The patent uses an intermediary approach by introducing calixarene derivatives as molecular mediators that interact with the glucocorticoid receptor to induce selective gene expression patterns. These compounds act as intermediaries that favorably modulate anti-inflammatory genes while avoiding activation of genes responsible for side effects, achieving the desired selectivity that previous direct agonists failed to accomplish.
Data Source
AI summary
Compounds of general Formula (I)wherein the elements A, L, R1 and R2 have a defined meaning, and their medical and non-medical use. The compounds may be used treatment of a subject in need of any one or more of anti-inflammatory, anti-oxidative, anti-ageing, or lipid metabolism modulation therapy or prophylaxis. The compounds may also be used as food or feed products, dietary supplements or cosmetic preparations.